肝癌患者肝动脉化疗栓塞术前后血清HBV载量变化研究

Changes of serum HBV DNA levels in patients with hepatocellular carcinoma before and after transcatheter arterial chemoebolization

目的探讨HBV阳性肝癌患者血清HBV载量在肝动脉化疗栓塞术介入治疗前、后的变化及其临床意义。方法选择44例HBV阳性肝癌患者,采用实时荧光定量PCR方法测定TACE介入治疗前、后患者血清的HBV载量。结果全组患者HBV DNA载量(Log10拷贝数/ml)与治疗前比较显著降低(P<0.05)。治疗1月后血清HBV DNA载量降低32例(72.7%),其中HBV DNA载量降为<500拷贝数/ml的有17例(38.6%),治疗无效21例。结论检测HBV DNA载量可作为HBV DNA阳性肝癌患者TACE治疗效果及肝癌预后的指标。

Objective To study the change of serum HBV DNA level in HBV positive hepatocellular carcinoma（HCC） patients before and after transcatheter arterial chemoebolization（TACE） and its clinical significance.Methods Serum HBV DNA levels were measured in 44 HBV positive HCC patients before and after TACE by real-time fluorescent quantitative PCR.Results The serum HBV DNA level（Log10 copies/ml） was significantly lower in all patients after TACE than before TACE（P0.05）.Of the 32 patients（72.7%） with their serum HBV DNA level（Log10 copies/ml） decreased one month after TACE,17（38.6%） had their serum level of HBV DNA level decreased to lower than 500 copies/ml,and 21 had no response to TACE.Conclusion Serum of HBV DNA level can be used as a marker of the efficacy of TACE in positive HBV DNA HCC patients.